<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630158</url>
  </required_header>
  <id_info>
    <org_study_id>CSAF312B12201</org_study_id>
    <nct_id>NCT04630158</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)</brief_title>
  <official_title>A 12-week Parallel Group, Randomized, Placebo-controlled, Double-blinded, Multi-center Study to Evaluate Efficacy and Safety of 2 Concentrations of SAF312 Eye Drops (5 mg/ml and 15 mg/ml) Used Twice-daily in the Treatment of Post-operative Corneal Induced Chronic Pain (CICP) Following Photorefractive Keratectomy (PRK) or Laser-assisted in Situ Keratomileusis (LASIK) Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to demonstrate the safety and efficacy of two dose concentrations of&#xD;
      SAF312 eye drops (dose 1 and dose 2) in subjects with CICP persisting at least for 4 months&#xD;
      after refractive surgery and chronicity confirmed during the observational period. The study&#xD;
      will also determine the optimal dose to carry forward for further development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 2 randomized, double-blinded, multi-center, parallel group,&#xD;
      placebo-controlled evaluation of the safety and efficacy of SAF312 dose 1 and dose 2 eye&#xD;
      drops versus placebo used twice-daily in both eyes for 12 weeks. Eligible subjects will have&#xD;
      undergone refractive surgery (PRK or LASIK) in both eyes at least 4 months prior to&#xD;
      Screening, and have been suffering from chronic ocular pain as a result of the their surgery.&#xD;
      Eligible patients must also demonstrate chronicity of the pain at Baseline Visit as described&#xD;
      in inclusion criteria. Overall approximately 150 subjects will be enrolled in the study and&#xD;
      randomized to one of 3 study arms in 1:1:1 ratio&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">December 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pain severity Visual Analog Scale</measure>
    <time_frame>84 days</time_frame>
    <description>To demonstrate the efficacy of at least 1 of 2 concentrations of SAF312 (dose 1 or dose 2) with superiority to placebo in reducing ocular pain severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain severity Visual Analog Scale</measure>
    <time_frame>Baseline, Day 7 and Day 14</time_frame>
    <description>To evaluate additional efficacy of 2 concentrations of SAF312 vs placebo (eg., time to pain severity improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain frequency Visual Analog Scale</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>To evaluate additional efficacy of 2 concentrations of SAF312 vs placebo (eg., time to pain frequency improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ocular Pain Assessment Scale (OPAS) sub-scale Quality of Life</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>To evaluate additional efficacy of 2 concentrations of SAF312 vs placebo (eg., time to improvement in quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular surface parameters (eg, corneal and conjunctival staining score, Schirmer score, conjunctival redness score)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>To evaluate if SAF312 has negative effects to the ocular surface after prolonged TRPV1 inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of adverse events rates between active and placebo</measure>
    <time_frame>Baseline, End of Study (Day 88)</time_frame>
    <description>To evaluate the safety of 2 concentrations of SAF312 (dose 1 and dose 2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Ocular Pain</condition>
  <arm_group>
    <arm_group_label>SAF312 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized to a 1:1:1 topical eye drops, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAF312 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to a 1:1:1 topical eye drops, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAF312 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to a 1:1:1 topical eye drops, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SAF312 Placebo</intervention_name>
    <description>Topical ocular, suspension eye drops,</description>
    <arm_group_label>SAF312 Placebo</arm_group_label>
    <other_name>Artificial tears</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAF312</intervention_name>
    <description>Topical ocular, suspension eye drops</description>
    <arm_group_label>SAF312 dose 1</arm_group_label>
    <arm_group_label>SAF312 dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have undergone PRK or LASIK surgery in both eyes ≥4 months prior to&#xD;
             Screening Visit and experiencing persistent ocular surface pain since the surgery, and&#xD;
             have been seen by an ophthalmologist at least once with complaint of continued ocular&#xD;
             pain since surgery.&#xD;
&#xD;
          -  Subjects who demonstrate a ≥ 60% reduction in ocular pain within 5 minutes after&#xD;
             instillation of a single topical ocular anesthetic drop at Screening Visit.&#xD;
&#xD;
        At Baseline&#xD;
&#xD;
          -  Subjects with moderate to severe ocular pain defined as an average pain severity VAS&#xD;
             score of ≥ 50 mm based on Daily eDiary for the last 7 days prior to Baseline Visit.&#xD;
&#xD;
          -  Subjects who have reported pain severity &gt;10 mm based on Daily eDiary for &gt; 50% of the&#xD;
             days of the observational period (Screening)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Use of nerve growth factor eye drops within 14 days of the Screening Visit&#xD;
&#xD;
          -  Seasonal allergic conjunctivitis, or other acute or seasonal ocular diagnosis that are&#xD;
             active at the time of Screening or would be active during the course of the study.&#xD;
&#xD;
          -  Any history of ocular herpes simplex virus or herpes zoster virus infection, or other&#xD;
             severe ocular conditions such as graft versus host disease, Stevens-Johnson syndrome&#xD;
             or sarcoidosis.&#xD;
&#xD;
          -  Presence of any ocular infection (bacterial, viral, or fungal) within 30 days prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Chronic topical ocular medications (ie. cyclosporine, lifitegrast) initiated &lt;6 months&#xD;
             prior to Screening Visit, or any anticipated change during the study.&#xD;
&#xD;
          -  Use of ocular or nasal corticosteroids within 30 days of Screening Visit.&#xD;
&#xD;
          -  Use of neuromodulatory medications (eg, gabapentin, pregabalin) or opioid use for&#xD;
             non-ocular pain within 30 days of Screening Visit.&#xD;
&#xD;
          -  Chronic medications (both over the counter and prescription) that have not been stable&#xD;
             for at least 30 days prior to Screening Visit, or any anticipated change in the&#xD;
             chronic medication regimen.&#xD;
&#xD;
          -  Subjects with severe psychiatric disorders (e.g. psychosis, schizophrenia, mania,&#xD;
             depression) or major psychiatric illness requiring recent hospitalization (ie, in the&#xD;
             last 6 months) or requiring treatment with more than one psychiatric medication (ie,&#xD;
             anti-depressants, anti-psychotics, anxiolytics).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maryville</city>
        <state>Tennessee</state>
        <zip>37803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eye pain</keyword>
  <keyword>Dry eye like symptoms</keyword>
  <keyword>Ocular surface pain</keyword>
  <keyword>Corneal induced chronic pain</keyword>
  <keyword>neuropathic eye pain</keyword>
  <keyword>post-operative corneal induced chronic pain</keyword>
  <keyword>CICP</keyword>
  <keyword>corneal</keyword>
  <keyword>corneal pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.</ipd_description>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

